Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)
OTCMKTS · Delayed Price · Currency is USD
9.36
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
SBLOF Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 31,374 | 32,413 | 26,450 | 25,090 | 17,748 | 15,110 | |
Revenue Growth (YoY) | 2.19% | 22.54% | 5.42% | 41.37% | 17.46% | 3.77% |
Cost of Revenue | 17,548 | 15,453 | 12,168 | 12,044 | 8,061 | 7,557 |
Gross Profit | 13,826 | 16,960 | 14,282 | 13,046 | 9,687 | 7,553 |
Selling, General & Admin | 8,792 | 11,062 | 8,116 | 6,830 | 4,908 | 4,482 |
Research & Development | 2,218 | 2,217 | 1,741 | 683 | 425 | 392 |
Operating Expenses | 11,707 | 13,975 | 10,120 | 7,801 | 5,491 | 5,024 |
Operating Income | 2,119 | 2,985 | 4,162 | 5,245 | 4,196 | 2,529 |
Interest Expense | -259.14 | -202 | -138 | -125 | -126 | -184 |
Interest & Investment Income | 171.34 | 98 | 188 | 58 | 8 | 2 |
Earnings From Equity Investments | 2,857 | 3,513 | 2,751 | 2,489 | 1,439 | 846 |
Currency Exchange Gain (Loss) | 235.78 | -162 | 60 | 1,511 | 1,370 | 239 |
Other Non Operating Income (Expenses) | 307.07 | 217 | -7 | 16 | 190 | 211 |
EBT Excluding Unusual Items | 5,431 | 6,449 | 7,016 | 9,194 | 7,077 | 3,643 |
Gain (Loss) on Sale of Investments | -152.81 | -131 | 51 | -1,327 | 1,381 | 1,173 |
Gain (Loss) on Sale of Assets | -225.72 | -228 | -50 | -13 | -21 | -4 |
Asset Writedown | -318.89 | -78 | -34 | -44 | -225 | -639 |
Other Unusual Items | - | - | -9 | -51 | -30 | - |
Pretax Income | 4,734 | 6,012 | 6,974 | 7,759 | 8,182 | 4,173 |
Income Tax Expense | 811.34 | 1,148 | 1,456 | 1,708 | 1,016 | 497 |
Earnings From Continuing Operations | 3,923 | 4,864 | 5,518 | 6,051 | 7,166 | 3,676 |
Minority Interest in Earnings | 67.46 | 60 | 13 | 9 | -39 | -15 |
Net Income | 3,990 | 4,924 | 5,531 | 6,060 | 7,127 | 3,661 |
Net Income to Common | 3,990 | 4,924 | 5,531 | 6,060 | 7,127 | 3,661 |
Net Income Growth | -19.26% | -10.97% | -8.73% | -14.97% | 94.67% | 43.57% |
Shares Outstanding (Basic) | 42 | 42 | 42 | 42 | 42 | 42 |
Shares Outstanding (Diluted) | 42 | 42 | 42 | 42 | 42 | 42 |
Shares Change (YoY) | - | - | - | -0.00% | - | - |
EPS (Basic) | 95.84 | 118.28 | 132.86 | 145.56 | 171.19 | 87.94 |
EPS (Diluted) | 95.84 | 118.28 | 132.86 | 145.56 | 171.19 | 87.94 |
EPS Growth | -19.26% | -10.97% | -8.73% | -14.97% | 94.67% | 43.57% |
Free Cash Flow | - | -3,818 | -6,476 | -834 | 4,410 | 3,679 |
Free Cash Flow Per Share | - | -91.71 | -155.56 | -20.03 | 105.93 | 88.37 |
Dividend Per Share | 50.000 | 50.000 | 50.000 | 50.000 | 30.000 | 10.000 |
Dividend Growth | - | - | - | 66.67% | 200.00% | 100.00% |
Gross Margin | 44.07% | 52.33% | 54.00% | 52.00% | 54.58% | 49.99% |
Operating Margin | 6.75% | 9.21% | 15.73% | 20.91% | 23.64% | 16.74% |
Profit Margin | 12.72% | 15.19% | 20.91% | 24.15% | 40.16% | 24.23% |
Free Cash Flow Margin | - | -11.78% | -24.48% | -3.32% | 24.85% | 24.35% |
EBITDA | 5,288 | 5,595 | 6,029 | 6,845 | 5,373 | 3,716 |
EBITDA Margin | 16.85% | 17.26% | 22.79% | 27.28% | 30.27% | 24.59% |
D&A For EBITDA | 3,168 | 2,610 | 1,867 | 1,600 | 1,177 | 1,187 |
EBIT | 2,119 | 2,985 | 4,162 | 5,245 | 4,196 | 2,529 |
EBIT Margin | 6.75% | 9.21% | 15.73% | 20.91% | 23.64% | 16.74% |
Effective Tax Rate | 17.14% | 19.10% | 20.88% | 22.01% | 12.42% | 11.91% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.